Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis [ID3834]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 21 February 2024